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The lack of appropriate health professional educa-
tion is considered a major barrier to the implementation
of pharmacogenomics in clinical practice. Pharmacoge-
nomics is important for personalized medicines and for
safer, more effective pharmacotherapy. In simple terms,
pharmacogenomics can improve the clinical outcomes of
pharmacotherapy by the use of genetic information. This
will lead to better medical care due to the better chance of
therapeutic success and the reduction of adverse effects. It
also may reduce health care costs by restricting use of
certain treatments to those who will get the most benefit.1
Worldwide, only a limited number of pharmacists use
pharmacogenomics in their practice and this is usually
in highly specialized roles. Yet, it is acknowledged that
pharmacists, as drug therapy experts, should have a greater
role incorporating pharmacogenomic information into pa-
tient care. There is a wide range of opportunities for phar-
macists in the field of pharmacogenomics.
Translational medicine is loosely defined as “the
process of applying ideas, insights, and discoveries gen-
erated through basic scientific research to the treatment or
prevention of human disease.” The International Society
of Pharmacogenomics has stated that pharmacogenomics
knowledge is necessary for incorporating personalizedmed-
icine approaches into routine clinical practice. To facilitate
translation, it is essential that pharmacists are fully prepared
for the use of pharmacogenomic diagnostic tools; however,
insufficient education and the resulting lack of knowledge
and contextual awareness of these tools will pose severe
barriers to the widespread implementation of personal-
ized medicine into clinical practice. This commentary
aims to highlight critical issues surrounding the develop-
ment of pharmaceutical education in order to accelerate
the acceptance of personalized medicine.
Two policy resolutions passed by the 2008American
Association of Colleges of Pharmacy (AACP) House of
Delegates recommended an increased focus on the advance-
ment of education in biotechnology.2 The first resolution
examined the curricular implications of biotechnology and
personalized medicine. It focused on the need for phar-
macy curricula to address up-to-date issues associated
with biotechnology advances in tailoredmedicine. Specific
competencies highlighted were cell and system biology,
bioengineering, genetics/genomics, proteomics, nanotech-
nology, cellular and tissue engineering, bio-imaging,
computational methods, and information technologies.
The second resolution focused on faculty development
in biotechnology. This policy stated that "faculty devel-
opment programs and collaborative research and teaching
strategies should be expanded such that faculty at colleges
and schools of pharmacy are prepared to lead and contrib-
ute significantly to education and research. . ."
Murphy and colleagues3 recently assessed the breadth
and depth of pharmacogenomics content instruction, the
importance of these topics as perceived by respondents,
and whether faculty development was available relative to
these areas inUS colleges of pharmacy. Themain finding of
this study was that the majority of colleges of pharmacy in
the US are now providing some pharmacogenomics within
their curriculum, indicating an increased awareness of the
need to do so, and thus demonstrating alignment with
AACP recommendations about including this material
within the PharmD curriculum. The secondary finding is
the somewhat limited focus in faculty development for
this subject matter.
Brock and colleagues stated how pharmacists in phar-
macogenomics have 3 distinct roles: discovering pharma-
cogenomics-based therapies andevaluating them inclinical
trial settings (researchers), teaching pharmacists and other
clinicians to apply pharmacogenomics modalities to
patient-specific situations(educators), and utilizing phar-
macogenomics information to recommend and monitor
patient-specific medication regimens (clinicians).4
Clemerson and colleagues proposed that advances
in pharmacogenetic testing may provide an opportunity
for pharmacists to take on new roles including providing
community pharmacy-based services.5 Pharmacists in the
future, they stated,may have responsibility for supporting
prescribing decisions through medicine selection and
dosage adjustment using pharmacogenetic information
and providing an easily accessible source of advice and
information on the subject to the public. They proposed
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that pharmacists would need greater access to patients’
medical records and that increased collaborationwith pre-
scribers will be essential to enable pharmacists to take on
roles in this area.
In the United Kingdom, Clemerson and Payne ac-
knowledged that fundamental understanding of the tech-
nologies used in pharmacogenomics is required and
therefore the education of the pharmacy profession needs
to be enhanced in this area.6 A report commissioned by
the Pharmacy Practice Research Trust identified certain
areas where pharmacy could participate.7 These included
translating scientific research findings into working tech-
nologies and new clinical practices, developing new ser-
vices, creating technical and organizational infrastructures
in areas such as genetic testing, increasing professional
knowledge and training, and establishing newgovernance
regimens.
McKinnon and colleagues identified that skill sets
required for the optimal participation of pharmacists in
pharmacogenomics and personalizedmedicine include ge-
netics, health economics, pharmacoepidemiology, model-
ling and simulation, therapeutics and regulatory pathways.1
In terms of educating pharmacists, their study found that
there was a disconnect between the identified barriers
thought to be limiting pharmacogenomics uptake and
the current status of pharmacogenomics material in phar-
macy curricula.
Through an Australian telephone survey, Plevin and
colleagues found that pharmacists possess an ideal skill
set for the optimal use of targeted therapies in cancer, but
that increased education relevant to targeted therapy in
cancer is required to harness this resource.8 Three general
ideas that emerged from the interviews regarding phar-
macy education around targeted therapies were that edu-
cation around targeted therapies is important, especially
given the recent availability of targeted therapies in com-
munity pharmacy; only a limited quantity of material
on this topic should be covered, at least at the undergrad-
uate level; and only appropriately trained pharmacists,
rather than pharmacists in general, should handle targeted
therapies.
Corkindale,Ward andMcKinnon studied the reasons
for low acceptance of pharmacogenetic tests in Australia
and found that accurate and rapid interpretation of test
results was a barrier to adoption of pharmacogenetics.9
They concluded that pharmacists could potentially fill this
gap in the health care system in a similar manner to which
therapeutic drug monitoring is conducted by pharmacists
at present. Given the widespread concerns of pharmacists
around the toxicities of many medicines, a greater phar-
macist involvement in using these tests could potentially
help to ameliorate toxicities where such tests exist. It was
highlighted that pharmacists could provide appropriate
pharmacogenomic information to clinicians and to patients,
thus becoming a valuable resource for consumers and help
to promote acceptance and use of pharmacogenomics.
Pharmacogenomics and its underpinning areas of ge-
netics, diagnostics, ethics, and regulatory affairs are a
compelling example of the need to teach pharmaceutical
science and practice in an integrated manner. Equally
important is the need to ensure that pharmacists are able
to effectively communicate about pharmacogenomics to
relevant groups, including with patients. We believe that
the educational strategies most likely to deliver these out-
comes involve the integration of pharmacogenomics ed-
ucation into existing therapeutics and clinical teaching
rather than as a standalone topic.
As the International Pharmaceutical Federation (FIP)
pharmacy education taskforce recently stated “because of
their knowledge of medicines and clinical therapeutics,
pharmacists are suitably placed for task shifting in health
care and could be further trained to undertake functions
such as clinical management and laboratory diagnostics. . .
A coordinated and multifaceted effort to advance work-
force planning, training and education is needed in order
to prepare an adequate number ofwell-trained pharmacists
for such roles.”10
There is still much to be done before pharmacoge-
nomics is routinely implemented into clinical practice and
personalized medicine becomes a reality, which high-
lights the need for transformation of pharmacogenomics
education. Further research and development is vital to be
able to propose the most appropriate structure for educa-
tion programs for pharmacy students and practicing phar-
macists, this could then aim to provide a detailed analysis
of the importance of education in facilitating increased
clinical acceptance and implementation of personalized
medicine.
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